Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Institute of Chemical Technology
Deal Size : Undisclosed
Deal Type : Partnership
Lasa partners with ICT to develop Favipiravir therapy for COVID 19
Details : Lasa is planning to approach DCGI for conducting required bioequivalence clinical trials in India, Once the Favipiravir therapy is approved by global regulatory authorities.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 16, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Institute of Chemical Technology
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?
Reset All
